POINT Biopharma Global Inc. logo

POINT Biopharma Global Inc.


Overview | Financials
Company Name POINT Biopharma Global Inc.
Symbol PNT
Currency USD
Price 12.5
Market Cap 1,332,112,500
Dividend Yield 0%
52-week-range 6.57 - 14.35
Industry Biotechnology
Sector Healthcare
CEO Dr. Joe A. McCann Ph.D.
Website https://www.pointbiopharma.com

An error occurred while fetching data.

About POINT Biopharma Global Inc.

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand,

Related Stocks

uniQure N.V. logo

uniQure N.V.


8.72 USD

Cross Country Healthcare, Inc. logo

Cross Country Healthcare, Inc.


13.79 USD

Design Therapeutics, Inc. logo

Design Therapeutics, Inc.


4.36 USD

Erasca, Inc. logo

Erasca, Inc.


2.97 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.


8.72 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.


0.47 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.


22.5 USD


Numbers are in millions USD

Numbers are in millions USD